WuXi Biologics Initiated cGMP Manufacturing in the World's Largest Biologics Manufacturing Facility Using Only Single-Use Bioreactors
WUXI, China, Dec. 6, 2017 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company, offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that its cGMP biologics manufacturing facility in Wuxi c...
WuXi Biologics and Pall Corporation Establish Joint Continuous Bioprocess Laboratory
SHANGHAI, Nov. 2, 2017 /PRNewswire/ -- WuXi Biologics (2269.HK), a global leading open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and its partner Pall Corporation, the global leader of advanced filtration, ...
WuXi Biologics Announces 2017 Interim Results
HONG KONG, Aug. 22, 2017 /PRNewswire/ -- WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announces...
WuXi Biologics and Gloria Pharmaceuticals Announce the Licensure of the Fully Human PD-1 Antibody, GLS-010, to Arcus Biosciences
SHANGHAI and BEIJING, Aug. 17, 2017 /PRNewswire/ -- WuXi Biologics (2269.HK), a global leading open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and its Chinese partner Harbin Gloria Pharmaceuticals Co Ltd (0...
WuXi Biologics is Officially Listed on the Hong Kong Stock Exchange
HONG KONG, June 13, 2017 /PRNewswire/ -- On June 13, 2017, WuXi Biologics (Cayman) Inc. ("the Company"; stock code: 2269.HK) was officially listed during a grand listing ceremony at the Main Board of The Stock Exchange ofHong Kong. Dr.Ge Li, Group Chairman and CEO of WuXi AppTec and Chairman o...
